Phase 1Completed

Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients

A Phase 1 Study to Evaluate the Pharmacokinetics and the Pharmacodynamics of TH9507 Administered Subcutaneously Once Daily for 14 Consecutive Days in HIV Positive Patients

Sponsor
Theratechnologies (Industry)
Enrollment
18 enrolled
Conditions
HIV
Interventions
Tesamorelin
Ages
adults, older adults
Registry
NCT02012556

Full record on ClinicalTrials.gov

From the registry

The primary objective of the study is to determine the PK (tesamorelin) and PD (IGF-1) profiles of tesamorelin after a single 2 mg subcutaneous administration and after repeated administration once daily for 14 consecutive days. Secondary objectives include the evaluation of the safety and tolerability of tesamorelin following multiple subcutaneous injections.

Primary outcomes

  • Area under the Plasma Concentration versus Time Curve (AUC) of Tesamorelin.
  • Peak Plasma Concentration (Cmax) of Tesamorelin.
  • Time to Maximum Plasma Concentration (Tmax) of Tesamorelin.
  • Apparent Elimination Half-life (T1/2 el) of Tesamorelin.

History

  1. Registered

  2. Primary completion

  3. Started